{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:49:40Z","timestamp":1794365380046,"version":"4.9.0"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Blood vessels in tumors are morphologically and functionally distinct from normal resting blood vessels. We probed lymphatic vessels in premalignant lesions and tumors by in vivo screening of phage-displayed peptide libraries, asking whether they too have distinctive signatures. The resulting peptides begin to define such signatures. One peptide identified the lymphatics in a human melanoma xenograft. Another recognized the lymphatics in prostate cancers but not in premalignant prostate lesions; this peptide similarly identifies human prostate cancer lymphatics. A third was selective for the lymphatics in the premalignant prostate lesions. A fourth identified the lymphatics in dysplasias and squamous carcinomas of the cervix and skin. None recognize lymphatics in normal tissues. Thus, tumor development is associated with organ- and stage-specific changes in lymphatics. Systemic treatment of mice with fusions of a lymphatic homing peptide and a proapoptotic motif reduced the number of tumor lymphatics in prostate tumor and melanoma, forecasting future lymphatic targeting agents for detection and therapeutic intervention. (Cancer Res 2006; 66(11): 5696-706)<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-3876","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T17:15:12Z","timestamp":1149182112000},"page":"5696-5706","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Lymphatic Zip Codes in Premalignant Lesions and Tumors"],"prefix":"10.1158","volume":"66","author":[{"given":"Lianglin","family":"Zhang","sequence":"first","affiliation":[{"name":"1Cancer Research Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Giraudo","sequence":"additional","affiliation":[{"name":"4Department of Biochemistry and Biophysics, and the Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"2Program in Molecular Pathology, Burnham Institute for Medical Research;"},{"name":"3Department of Pathology, University of California San Diego, School of Medicine, La Jolla, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Hanahan","sequence":"additional","affiliation":[{"name":"4Department of Biochemistry and Biophysics, and the Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Ruoslahti","sequence":"additional","affiliation":[{"name":"1Cancer Research Center and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,6,1]]},"reference":[{"key":"2022061621044868200_B1","doi-asserted-by":"crossref","unstructured":"Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer\u20082002; 2: 83\u201390.","DOI":"10.1038\/nrc724"},{"key":"2022061621044868200_B2","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell\u20082000; 100: 57\u201370.","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"2022061621044868200_B3","unstructured":"Brooks PG, Clouse J, Morris LS. Hysterectomy vs. resectoscopic endometrial ablation for the control of abnormal uterine bleeding. A cost-comparative study. J Reprod Med\u20081994; 39: 755\u201360."},{"key":"2022061621044868200_B4","doi-asserted-by":"crossref","unstructured":"Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol\u20082003; 163: 871\u20138.","DOI":"10.1083\/jcb.200304132"},{"key":"2022061621044868200_B5","doi-asserted-by":"crossref","unstructured":"Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med\u20081999; 5: 1359\u201364.","DOI":"10.1038\/70928"},{"key":"2022061621044868200_B6","unstructured":"Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res\u20082000; 60: 722\u20137."},{"key":"2022061621044868200_B7","doi-asserted-by":"crossref","unstructured":"Hoffman JA, Giraudo E, Singh M, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell\u20082003; 4: 383\u201391.","DOI":"10.1016\/S1535-6108(03)00273-3"},{"key":"2022061621044868200_B8","doi-asserted-by":"crossref","unstructured":"Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell\u20082003; 4: 393\u2013403.","DOI":"10.1016\/S1535-6108(03)00271-X"},{"key":"2022061621044868200_B9","doi-asserted-by":"crossref","unstructured":"Cao R, Bjorndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell\u20082004; 6: 333\u201345.","DOI":"10.1016\/j.ccr.2004.08.034"},{"key":"2022061621044868200_B10","doi-asserted-by":"crossref","unstructured":"Cassella M, Skobe M. Lymphatic vessel activation in cancer. Ann N Y Acad Sci\u20082002; 979: 120\u201330.","DOI":"10.1111\/j.1749-6632.2002.tb04873.x"},{"key":"2022061621044868200_B11","doi-asserted-by":"crossref","unstructured":"Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer\u20082002; 2: 573\u201383.","DOI":"10.1038\/nrc863"},{"key":"2022061621044868200_B12","doi-asserted-by":"crossref","unstructured":"Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol\u20082001; 22: 317\u201321.","DOI":"10.1016\/S1471-4906(01)01936-6"},{"key":"2022061621044868200_B13","doi-asserted-by":"crossref","unstructured":"Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med\u20082002; 8: 751\u20135.","DOI":"10.1038\/nm720"},{"key":"2022061621044868200_B14","doi-asserted-by":"crossref","unstructured":"Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science\u20082002; 296: 1883\u20136.","DOI":"10.1126\/science.1071420"},{"key":"2022061621044868200_B15","doi-asserted-by":"crossref","unstructured":"Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J\u20082001; 20: 672\u201382.","DOI":"10.1093\/emboj\/20.4.672"},{"key":"2022061621044868200_B16","doi-asserted-by":"crossref","unstructured":"Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med\u20082001; 7: 192\u20138.","DOI":"10.1038\/84643"},{"key":"2022061621044868200_B17","doi-asserted-by":"crossref","unstructured":"Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol\u20082004; 25: 387\u201395.","DOI":"10.1016\/j.it.2004.05.003"},{"key":"2022061621044868200_B18","doi-asserted-by":"crossref","unstructured":"Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware JL. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate\u20081998; 34: 275\u201382.","DOI":"10.1002\/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G"},{"key":"2022061621044868200_B19","doi-asserted-by":"crossref","unstructured":"Arbeit JM, Munger K, Howley PM, Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol\u20081994; 68: 4358\u201368.","DOI":"10.1128\/jvi.68.7.4358-4368.1994"},{"key":"2022061621044868200_B20","doi-asserted-by":"crossref","unstructured":"Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A\u20081996; 93: 2930\u20135.","DOI":"10.1073\/pnas.93.7.2930"},{"key":"2022061621044868200_B21","doi-asserted-by":"crossref","unstructured":"Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest\u20082004; 114: 623\u201333.","DOI":"10.1172\/JCI200422087"},{"key":"2022061621044868200_B22","doi-asserted-by":"crossref","unstructured":"Hoffman J, Laakkonen P, Porkka K, Bernasconi M, Ruoslahti E. In vivo and ex vivo selections using phage-displayed libraries. In: Clackson T, Lowman HB, editors. Phage display. New York: Oxford University Press; 2004. p. 171\u201392.","DOI":"10.1093\/oso\/9780199638734.003.0010"},{"key":"2022061621044868200_B23","doi-asserted-by":"crossref","unstructured":"Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A\u20081995; 92: 3439\u201343.","DOI":"10.1073\/pnas.92.8.3439"},{"key":"2022061621044868200_B24","doi-asserted-by":"crossref","unstructured":"Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol\u20081996; 24: 502\u20134.","DOI":"10.1177\/019262339602400414"},{"key":"2022061621044868200_B25","doi-asserted-by":"crossref","unstructured":"Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A\u20082004; 101: 9381\u20136.","DOI":"10.1073\/pnas.0403317101"},{"key":"2022061621044868200_B26","doi-asserted-by":"crossref","unstructured":"Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med\u20081999; 5: 1032\u20138.","DOI":"10.1038\/12469"},{"key":"2022061621044868200_B27","doi-asserted-by":"crossref","unstructured":"Arap W, Haedicke W, Bernasconi M, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A\u20082002; 99: 1527\u201331.","DOI":"10.1073\/pnas.241655998"},{"key":"2022061621044868200_B28","doi-asserted-by":"crossref","unstructured":"Hsu CX, Ross BD, Chrisp CE, et al. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol\u20081998; 160: 1500\u20135.","DOI":"10.1016\/S0022-5347(01)62603-X"},{"key":"2022061621044868200_B29","unstructured":"Coussens LM, Hanahan D, Arbeit JM. Genetic predisposition and parameters of malignant progression in K14-16 transgenic mice. Am J Pathol\u20081996; 149: 1899\u2013917."},{"key":"2022061621044868200_B30","unstructured":"Mouta Carreira C, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res\u20082001; 61: 8079\u201384."},{"key":"2022061621044868200_B31","doi-asserted-by":"crossref","unstructured":"Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol\u20081999; 154: 1381\u201390.","DOI":"10.1016\/S0002-9440(10)65392-8"},{"key":"2022061621044868200_B32","doi-asserted-by":"crossref","unstructured":"Arap W, Pasqualini R, Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr Opin Oncol\u20081998; 10: 560\u20135.","DOI":"10.1097\/00001622-199811000-00014"},{"key":"2022061621044868200_B33","doi-asserted-by":"crossref","unstructured":"Yao VJ, Ozawa MG, Trepel M, Arap W, McDonald DM, Pasqualini R. Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. Am J Pathol\u20082005; 166: 625\u201336.","DOI":"10.1016\/S0002-9440(10)62283-3"},{"key":"2022061621044868200_B34","doi-asserted-by":"crossref","unstructured":"Ruoslahti E. The RGD story: a personal account. Matrix Biol\u20082003; 22: 459\u201365.","DOI":"10.1016\/S0945-053X(03)00083-0"},{"key":"2022061621044868200_B35","doi-asserted-by":"crossref","unstructured":"Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med\u20082001; 7: 186\u201391.","DOI":"10.1038\/84635"},{"key":"2022061621044868200_B36","doi-asserted-by":"crossref","unstructured":"Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res\u20082005; 65: 6901\u20139.","DOI":"10.1158\/0008-5472.CAN-05-0408"},{"key":"2022061621044868200_B37","doi-asserted-by":"crossref","unstructured":"Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A. Coupling tumor necrosis factor-\u03b1 with \u03b1V integrin ligands improves its antineoplastic activity. Cancer Res\u20082004; 64: 565\u201371.","DOI":"10.1158\/0008-5472.CAN-03-1753"},{"key":"2022061621044868200_B38","doi-asserted-by":"crossref","unstructured":"Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor \u03b1 antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol\u20082000; 18: 1185\u201390.","DOI":"10.1038\/81183"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/11\/5696\/2548964\/5696.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/11\/5696\/2548964\/5696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T11:55:24Z","timestamp":1707047724000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/11\/5696\/525643\/Lymphatic-Zip-Codes-in-Premalignant-Lesions-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2006,6,1]]},"published-print":{"date-parts":[[2006,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-3876","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6494205.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6494205","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22364469","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22364472.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22364472","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22364475","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22364475.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22364469.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,1]]}}}